GlassScriptPhysician profile
Afton Leuga
NPI 1902308455
$3,179.80
in general payments reported to CMS, 2019-2025
20 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $295 · 2022: $1,260 · 2023: $823 · 2024: $646 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,237.07 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $568.23 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $469.66 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $212.37 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Lilly USA, LLC | $103.92 | 2022-2023 | Lyumjev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.06 | 2021-2024 | Jardiance |
| Ascensia Diabetes Care US INC. | $61.50 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.26 | 2022-2023 | |
| Becton, Dickinson and Company | $48.18 | 2022 | |
| Medtronic, INC. | $47.94 | 2021-2024 | Minimed 780g |
| Neurocrine Biosciences, INC. | $47.10 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $43.28 | 2021-2024 | |
| Corcept Therapeutics | $41.22 | 2021-2025 | Korlym |
| Novo Nordisk INC | $30.02 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $24.37 | 2024 | Recorlev |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $23.82 | 2025 | Cequr Simplicity |
| Amgen INC. | $22.93 | 2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $21.52 | 2024 | |
| Madrigal Pharmaceuticals | $18.64 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afton Leuga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.